This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Telli, M. L. Articles by Guardino, A. E. Search for Related Content PubMed PubMed Citation Articles by Telli, M. L. Articles by Guardino, A. E. Related Articles Related Correspondence

Trastuzumab-Related Cardiotoxicity: Calling Into Question the Concept of Reversibility

Melinda L. Telli, Sharon A. Hunt, Robert W. Carlson, Alice E. Guardino

From the Department of Medicine, Division of Medical Oncology and Division of Cardiovascular Medicine, Stanford University, Stanford, CA

Address reprint requests to Alice E. Guardino, MD, PhD, 875 Blake Wilbur Dr, Stanford, CA 94305; e-mail: guardino{at}stanford.edu

Purpose: To assess the spectrum and reversibility of the cardiotoxicity observed in the adjuvant trastuzumab trials.

Design: The design and efficacy of the major adjuvant trastuzumab trials was assessed, including the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-31, North Central Cancer Treatment Group N9831, Herceptin Adjuvant, Breast Cancer International Research Group 006, and Finland Herceptin trials. The cardiotoxicity data were evaluated with a focus on the follow-up cardiac evaluations of women who were diagnosed with cardiotoxicity. Proposed mechanisms of trastuzumab-related cardiotoxicity were considered. The natural history of congestive heart failure (CHF) was reviewed with the goal of placing the trastuzumab experience in context.

Results: Up to 4% of patients enrolled onto the adjuvant trastuzumab trials experienced severe CHF during treatment. In these trials, early stopping rules that identified an unacceptable level of cardiotoxicity were never reached. Despite this, a large number of patients on these trials experienced some form of cardiotoxicity that ultimately required discontinuation of trastuzumab. Approximately 14% of patients in the NSABP B-31 trial discontinued trastuzumab because of asymptomatic decreases in left ventricular ejection fraction (LVEF). Results of follow-up cardiac evaluations of patients diagnosed with any degree of cardiotoxicity in the NSABP B-31 trial document that a clinically significant proportion of patients have sustained decrements in their LVEF to less than 50%.

Conclusion: Adjuvant trastuzumab provides substantial benefits to patients with human epidermal growth factor receptor 2–positive breast cancer, however, competing immediate and long-term cardiovascular risks are a great concern. Continued cardiac follow-up of these women is of critical importance.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

Related Correspondence

• Reversibility of Trastuzumab Cardiotoxicity: Is the Concept Alive and Well?
  Michael S. Ewer and Elizabeth Tan-Chiu
  JCO 2007 25: 5532-5533 [Full Text]

This article has been cited by other articles:

				M. L. Telli, R. M. Witteles, G. A. Fisher, and S. Srinivas Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Ann. Onc., September 1, 2008; 19(9): 1613 - 1618. [Abstract] [Full Text] [PDF]

				D. Rayson, D. Richel, S. Chia, C. Jackisch, S. van der Vegt, and T. Suter Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies Ann. Onc., September 1, 2008; 19(9): 1530 - 1539. [Abstract] [Full Text] [PDF]

				L. Gianni, E. H. Herman, S. E. Lipshultz, G. Minotti, N. Sarvazyan, and D. B. Sawyer Anthracycline Cardiotoxicity: From Bench to Bedside J. Clin. Oncol., August 1, 2008; 26(22): 3777 - 3784. [Abstract] [Full Text] [PDF]

				M. H. Chen, R. Kerkela, and T. Force Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics Circulation, July 1, 2008; 118(1): 84 - 95. [Full Text] [PDF]

				B. L. Frei and S. A. Soefje A Review of the Cardiovascular Effects of Oncology Agents Journal of Pharmacy Practice, April 1, 2008; 21(2): 146 - 158. [Abstract] [PDF]

				E. L. Mayer and H. J. Burstein Weighing a Dose-Dense Option for Adjuvant Chemotherapy and Trastuzumab in Early-Stage Breast Cancer J. Clin. Oncol., March 10, 2008; 26(8): 1198 - 1200. [Full Text] [PDF]

				M. S. Ewer and D. J. Lenihan Left Ventricular Ejection Fraction and Cardiotoxicity: Is Our Ear Really to the Ground? J. Clin. Oncol., March 10, 2008; 26(8): 1201 - 1203. [Full Text] [PDF]

				M. S. Ewer and E. Tan-Chiu Reversibility of Trastuzumab Cardiotoxicity: Is the Concept Alive and Well? J. Clin. Oncol., December 1, 2007; 25(34): 5532 - 5533. [Full Text] [PDF]